Difference between revisions of "Medical Reporting/Research - Academic and Professional"
Jump to navigation
Jump to search
(→Peer-Reviewed Research) |
(→Peer-Reviewed Research) |
||
| Line 5: | Line 5: | ||
=Peer-Reviewed Research= | =Peer-Reviewed Research= | ||
| + | * 22 MAY 2020 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial] | ||
* 14 MAY 2020 [https://www.cell.com/cell/fulltext/S0092-8674(20)30610-3 Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals] | * 14 MAY 2020 [https://www.cell.com/cell/fulltext/S0092-8674(20)30610-3 Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals] | ||
* 30 APR 2020 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial] | * 30 APR 2020 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial] | ||
Latest revision as of 03:32, 24 May 2020
Minimal Requirement of being a verified major news outlet with a high unbiased rating on The Media Bias Chart and/or from reputable sources, such as research facilities and universities
Strong recommendation to not take action or make assumptions based upon research which may be dated, changing or part of ongoing research
Pre-Requisite Reading: The Problem with Thinking You Know More Than the Experts
Peer-Reviewed Research
- 22 MAY 2020 Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- 14 MAY 2020 Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals
- 30 APR 2020 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- 27 APR 2020 Obesity: the “Achilles heel” for COVID-19?
- 24 APR 2020 The Use of Povidone Iodine Nasal Spray and Mouthwash During the Current COVID-19 Pandemic May Reduce Cross Infection and Protect Healthcare Workers
- 20 APR 2020 Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 - (PDF)
- 17 APR 2020 Guillain–Barré Syndrome Associated with SARS-CoV-2 Guillain–Barré Syndrome Associated with SARS-CoV-2
- 14 APR 2020 SIGMA-1 RECEPTOR MAY PLAY A KEY ROLE IN THE TREATMENT OF COVID-19
- 14 APR 2020 Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
- 13 APR 2020 Loss of Smell and Taste Validated as COVID-19 Symptoms in Patients with High Recovery Rate
- 06 APR 2020 Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans
- 01 APR 2020 Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19
- 24 MAR 2020 Investigating Decontamination and Reuse of Respirators in Public Health Emergencies
- 10 MAR 2020 The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application
- 25 FEB 2020 Laboratory diagnosis of emerging human coronavirus infections – the state of the art
- 14 FEB 2020 Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study
- 06 FEB 2020 Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020
- 00 SEP 2015 Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection
